Abstract
This article provides an overview of the evolution of revascularization devices since Grüntzig’s initial introduction of balloon angioplasty in 1977. In-stent restenosis (ISR) is the major shortcoming of conventional (permanent-implant) stent therapy; even with the innovation and promising benefits of drug-eluting stents, management of ISR is very difficult. ISR is mainly caused by the interaction between the blood and the stent surface and a permanent mechanical irritation of the vascular tissue. Thus stenting technology has moved toward the development of temporary implants composed of biocompatible materials which mechanically support the vessel during the period of high risk for recoil and then completely biodegrade in the long term. Preclinical and first clinical experiences with bioabsorbable magnesium stents are discussed.
Similar content being viewed by others
References
Grüntzig A, Schneider HJ (1977) The percutaneous dilatation of chronic coronary stenoses: Experiments and morphology. Schweiz Med Wochenschr 107:1588
Sigwart U, Puel J, Mirkovitch V, et al (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701–706
Hall P, Nakamura S, Maiello L, et al (1996) A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93:215–222
Colombo A, Hall P, Nakamura S, et al (1995) Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91:1676–1688
Colombo A, Ferraro M, Itoh A, et al (1996) Results of coronary stenting for restenosis. J Am Coll Cardiol 28:830–836
Mehran R, Dangas G, Abizaid AS, et al (1999) Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 100:1872–1878
Spanos V, Stankovic G, Tobis J, et al (2003) The challenge of in-stent restenosis: Insights from intravascular ultrasound. Eur Heart J 24:138–150
Bennett MR (2003) In-stent stenosis: Pathology and implications for the development of drug eluting stents. Heart 89:218–224
Rajagopal V, Rockson SG (2003) Coronary restenosis: A review of mechanisms and management. Am J Med 115:547–553
Apisarnthanarax S, Chougule P (2003) Intravascular brachytherapy: A review of the current vascular biology. Am J Clin Oncol 26:e13–21
Indolfi C, Mongiardo A, Curcio A, et al (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 13:142–148
Mintz GS, Popma JJ, Pichard AD, et al (1996) Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 94:35–43
Hoffmann R, Mintz GS, Dussaillant GR, et al (1996) Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94:1247–1254
Nakamura S, Colombo A, Gaglione A, et al (1994) Intracoronary ultrasound observations during stent implantation. Circulation 89:2026–2034
Virmani R, Farb A (1999) Pathology of in-stent restenosis. Curr Opin Lipidol 10:499–506
Grewe PH, Deneke T, Machraoui A, et al (2000) Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 35:157–163
Regar E, Sianos G, Serruys PW (2001) Stent development and local drug delivery. Br Med Bull 59:227–248
Condado JA, Waksman R, Gurdiel O, et al (1997) Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation 96:727–732
Waksman R, Bhargava B, Chan RC, et al (2001) Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. Cardiovasc Radiat Med 2:63–68
Teirstein PS, Massullo V, Jani S, et al (1997) Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336:1697–1703
Saia F, Lemos PA, Hoye A, et al (2004) Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 62:283–288
Costa MA, Sabat M, van der Giessen WJ, et al (1999) Late coronary occlusion after intracoronary brachytherapy. Circulation 100:789–792
Waksman R (1999) Late thrombosis after radiation. Sitting on a time bomb. Circulation 100:780–782
Doriot PA, Dorsaz PA, Verin V (2003) A morphological-mechanical explanation of edge restenosis in lesions treated with vascular brachytherapy. Cardiovasc Radiat Med 4:108–115
Serruys PW, van Hout B, Bonnier H, et al (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352:673–681
Lowe HC, Oesterle SN, Khachigian LM (2002) Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 39:183–193
Beyar R (2004) Novel approaches to reduce restenosis. Ann N Y Acad Sci 1015:367–378
Ong AT, Aoki J, McFadden EP, et al (2004) Classification and current treatment options of in-stent restenosis. Present status and future perspectives. Herz 29:187–194
Woods TC, Marks AR (2004) Drug-eluting stents. Annu Rev Med 55:169–178
Duda SH, Pusich B, Richter G, et al. (2002) Sirolimus-eluting stents for the treatment of obstructive superficial femoral arte\rventions in iliac and infrainguinal occlusive artery disease. J Interv Cardiol 17:427–435
Ruef J, Hofmann M, Haase J (2004) Endovascular interventions in iliac and infrainguinal occlusive artery disease. J Interv Cardiol 17:427–435
Palmaz JC (1997) New advances in endovascular technology. Tex Heart Inst J 24:156–159
Palmaz JC, Bailey S, Marton D, et al (2002) Influence of stent design and material composition on procedure outcome. J Vasc Surg 36:1031–1039
Zidar J, Lincoff A, Stack R (1994) Biodegradable stents. In: Topol EJ (ed) Textbook of interventional cardiology, 2nd edn. Saunders, Philadelphia, pp 787–802
Colombo A, Karvouni E (2000) Biodegradable stents: “Fulfilling the mission and stepping away.” Circulation 102:371–373
Wintermantel E, Mayer J, Ruffieux K, et al (1999) Biomaterials, human tolerance and integration. Chirurgie 70:847–857
Heublein B, Rohde R, Kaese V, et al (2003) Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart 89:651–656
Stack RS, Califf RM, Phillips HR, et al (1988) Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 62:3F–24F
Labinaz M, Zidar JP, Stack RS, et al (1995) Biodegradable stents: The future of interventional cardiology? J Interv Cardiol 8:395–405
Tanguay JF, Zidar JP, Phillips HR, 3rd, et al (1994) Current status of biodegradable stents. Cardiol Clin 12:699–713
van der Giessen WJ, Lincoff AM, Schwartz RS, et al (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94:1690–1697
Lincoff AM, Furst JG, Ellis SG, et al (1997) Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29:808–816
Tamai H, Igaki K, Kyo E, et al (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404
Yamawaki T, Shimokawa H, Kozai T, et al (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786
Vogt F, Stein A, Rettemeier G, et al (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340
Peuster M, Wohlsein P, Brugmann M, et al (2001) A novel approach to temporary stenting: Degradable cardiovascular stents produced from corrodible metal-results 6–18 months after implantation into New Zealand white rabbits. Heart 86:563–569
Sawyer P, Brattain W, Boddy P (1965) Electrochemical criteria in the choice of materials used in vascular prosthesis. In: Sawyer P (ed) Biophysical mechanism in vascular hemostasis and intravascular thrombosis. Appleton-Century-Crofts, New York, pp 337–348
Ferrando W (1989) Review of corrosion and corrosion control of magnesium alloys and composites. J Mater Eng 11:4
Sarma P, Gambihr S (1995) Therapeutic use of magnesium. Ind J Pharmacol 27:7–13
Vitale JJ (1992) Magnesium deficiency and cardiovascular disease. Lancet 340:1224–1225
Arsenian MA (1993) Magnesium and cardiovascular disease. Prog Cardiovasc Dis 35:271–310
Altura BM, Altura BT (1993) Cardiovascular risk factors and magnesium: Relationships to atherosclerosis, ischemic heart disease and hypertension. Schriftenr Ver Wasser Boden Lufthyg 88:451–473
Keller KB, Lemberg L (1993) The importance of magnesium in cardiovascular disease. Am J Crit Care 2:348–350
Kayser SR, Trujillo T (1994) The role of magnesium in cardiovascular disease. Prog Cardiovasc Nurs 9:37–40
Gomez MN (1998) Magnesium and cardiovascular disease. Anesthesiology 89:222–240
Sthülinger H (2002) Magnesium in cardiovascular disease. J Clin Basic Cardiol 5:55–59
Erne P, Buehler F, Kiowski W (1985) Physiologie des zellulärem Kalziumstoffwechsels. In: Bönner G, Dominiak D (eds) Kalziumantagonisten. Schattauer, Stuttgart, pp 11–37
Erne P, Pletscher A (1985) Vasopressin-induced activation of human blood platelets: Prominent role of Mg2+. Naunyn Schmiedebergs Arch Pharmacol 329:97–99
Peeters P, Bosiers M, Verbist J, et al. (2005) Preliminary short term results after application of absorbable metal stents in patients with critical limb ischemia. J Endovasc Ther 12:1–5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erne, P., Schier, M. & Resink, T.J. The Road to Bioabsorbable Stents: Reaching Clinical Reality?. Cardiovasc Intervent Radiol 29, 11–16 (2006). https://doi.org/10.1007/s00270-004-0341-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-004-0341-9